Emicizumab and Osimertinib Mesylate

• Generic Name: emicizumab
• Dosage Forms: n.a.
• Other Brand Names: Hemlibra, Hemlibra 105 mg/07 mL, Hemlibra 60 mg/04 mL

Emicizumab functions in place of a natural blood-clotting factor that is missing in people with hemophilia A. Emicizumab works as a "bridge" between other clotting factors to replace missing factor VIII.

Emicizumab is for adults and children with hemophilia A, with or without factor VIII inhibitors. Emicizumab is used to help prevent bleeding episodes or make them occur less often.

Emicizumab will not stop a bleeding episode that has already begun.

Emicizumab may also be used for purposes not listed in this medication guide.

• Generic Name: osimertinib
• Dosage Forms: n.a.
• Other Brand Names: Tagrisso

First-line treatment of metastatic NSCLC in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution mutations (as detected by an FDA-approved diagnostic test).

Treatment of metastatic NSCLC in patients with EGFR T790M mutation (as detected by an FDA-approved diagnostic test) who have experienced disease progression during or after EGFR tyrosine kinase inhibitor therapy.

Designated an orphan drug by FDA for treatment of EGFR mutation-positive NSCLC.